Market Segmentation:
- By Product Type
- Thrombectomy Devices
- Thrombolytics
- Anticoagulants
- Antiplatelets
- Others (e.g., neuroprotective agents, stem cell therapies)
- By End-User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Emergency Medical Services
- Others (e.g., home care settings)
- By Stroke Type
- Ischemic Stroke
- Hemorrhagic Stroke
- Transient Ischemic Attack (TIA)
- By Patient Age
- Geriatric (65 years and above)
- Adult (18-64 years)
- Pediatric (0-17 years)
- By Treatment Approach
- Thrombolytic Therapy
- Mechanical Thrombectomy
- Combination Therapy
- Conservative Management
- Others (e.g., surgery, neuroprotection)
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East, and Africa
Frequently Asked Questions
The current market size of the Acute Ischemic Stroke (AIS) industry is estimated to be US$ 8,450 million as of 2023.
The key factors contributing significantly to the growth of the Acute Ischemic Stroke (AIS) market include the rising prevalence of stroke, the growing geriatric population, advancements in stroke diagnostics, and the development of innovative treatment options.
The key factors hampering the growth of the Acute Ischemic Stroke (AIS) market include the high cost of stroke treatment devices and medications, limited access to stroke care in certain regions, the risk of complications and side effects with stroke therapies, and reimbursement challenges for advanced stroke treatments.
The leading component segment in the Acute Ischemic Stroke (AIS) Market is the thrombectomy devices segment, which is used to mechanically remove blood clots from the brain and restore blood flow.
The major players operating in the Acute Ischemic Stroke (AIS) Market include Medtronic plc, Stryker Corporation, Johnson & Johnson, Penumbra, Inc., Terumo Corporation, Koninklijke Philips N.V., Genentech, Inc. (Roche), Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, and Pfizer Inc.
The Acute Ischemic Stroke (AIS) Market is expected to grow at a CAGR of 8.7% from 2023 to 2030, reaching a market size of US$ 16,470 million by 2031.
The key drivers of the Acute Ischemic Stroke (AIS) Market include the rising incidence of stroke, the growing geriatric population, advancements in stroke diagnostics, the development of innovative treatment options, and the increasing adoption of minimally invasive stroke interventions.